The data show that a regimen based on Trodelvy and PD-1 inhibitor Keytruda (pembrolizumab) was better than Keytruda plus ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

March was a light month across the board for hires news, but the digital and supplier sectors in biopharma saw a spat of ...